Oncotype DX Breast Recurrence Score

Interpreting the Results

Genomic Health makes understanding Oncotype DX Breast Recurrence Score test results as easy as possible. A detailed Breast Recurrence Score report is generated for each patient. The report contains the Recurrence Score result—a number between 0-100—that assesses the 9-year risk of distant recurrence1 in node-negative patients, 5-year distant recurrence or mortality in node-positive3 patients and the likelihood that chemotherapy will benefit your patient.2,4

Interactive Report Guide

A quick and intuitive explanation of what to look for in each Breast Recurrence Score report.

The relevance of the ER score

The quantitative ER score by RT-PCR has been shown to be a strong predictor of tamoxifen benefit5 in node-negative patients. While the Recurrence Score result and corresponding average rate of distant recurrence accounts for this effect of tamoxifen (in addition to the tumor’s fundamental prognosis), the single-gene ER score may also help clarify the magnitude of tamoxifen benefit.

How your patient’s score is generated

The Breast Recurrence Score test is a genomic test—that measures the expression of cancer-related genes in your patient’s tumor. Your patient’s score is based on the expression of 21 specific genes from tumor tissue removed during the surgery or core biopsy. Looking at the expression of this unique set of genes the score provides important information about how likely your patient’s cancer is to return and the likelihood of benefit from chemotherapy. Learn more about how the test works.

Getting the results

Most Recurrence Score results are available within two weeks from the date the specimen is received in the Genomic Health lab. You can access the results through the online physician portal or receive the report by fax.

START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
REFERENCES

1. Paik et al. N Engl J Med. 2004.
2. Paik et al. J Clin Oncol. 2006.
3. Dowsett et al. J Clin Oncol. 2010.
4. Albain et al. Lancet Oncol. 2010.
5. Kim et al. J Clin Oncol. 2010.

This content is intended for healthcare professionals only. If you are not a healthcare professional, click here for more information

For Patients

Prospective Outcomes:
TAILORx

The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results were published in The New England Journal of Medicine

Read Full Text

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.